Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):14790. https://doi.org/10.1038/s41598-020-71908-9. (Internet).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice. 2021;183(109119):109119. https://doi.org/10.1016/j.diabres.2021.109119.

Article  PubMed  PubMed Central  Google Scholar 

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. https://doi.org/10.1016/j.diabres.2009.10.007. (Internet).

Article  CAS  PubMed  Google Scholar 

Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. CurrOpin Immunol. 1995;7(1):54–64. https://doi.org/10.1016/0952-7915(95)80029-8. (Internet).

Article  CAS  Google Scholar 

Nauta AJ, De Haij S, Bottazzi B, Mantovani A, Borrias MC, Aten J, et al. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int. 2005;67(2):543–53. https://doi.org/10.1111/j.1523-1755.2005.67111.x. (Internet).

Article  CAS  PubMed  Google Scholar 

Zhu H, Yu W, Xie Y, Zhang H, Bi Y, Zhu D. Association of pentraxin 3 gene polymorphisms with susceptibility to diabetic nephropathy. Med Sci Monit [Internet]. 2017;23:428–36.

Article  CAS  PubMed  Google Scholar 

Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(4):976–85. https://doi.org/10.2215/CJN.03960907. (Internet).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prasad RM, Bali A, Tikaria R. Microalbuminuria. [Updated 2023 May 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563255/.

Zelmanovitz T, Gerchman F, Balthazar AP, et al. Diabetic nephropathy Diabetol Metab Syndr. 2009;1:10. https://doi.org/10.1186/1758-5996-1-10.

Article  CAS  PubMed  Google Scholar 

Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016;9(5):504–12. https://doi.org/10.1161/circoutcomes.116.002901. (Internet).

Article  PubMed  PubMed Central  Google Scholar 

Wang R, Zhang J, Hu W. Association of serum pentraxin 3 concentrations with diabetic nephropathy. J Investig Med. 2016;64(6):1124–7. https://doi.org/10.1136/jim-2016-000082. (Internet).

Article  PubMed  Google Scholar 

Uzun S, Ozari M, Gursu M, Karadag S, Behlul A, Sari S, et al. Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3. Ren Fail. 2016;38(8):1193–8. https://doi.org/10.1080/0886022x.2016.1209031. (Internet).

Article  CAS  PubMed  Google Scholar 

Dawood AA, Kamel MA, Omar TA. Study of serum pentraxin 3 level in patients with diabetic nephropathy. Egypt J Intern Med. 2020;32(1). https://doi.org/10.1186/s43162-020-00002-3.

Al-Barshomy S, Mostafa ME, Shaker G, Wahab L. Serum and urinary pentraxin-3 levels in type 2 diabetes and its relation to diabetic nephropathy. Egypt J Intern Med. 2018;30(4):182. https://doi.org/10.4103/ejim.ejim_9_18. (Internet).

Article  Google Scholar 

El-Senosy F, Elwakeel ME, Mohamed RE. Study of pentraxin-3 as an early marker of diabetic nephropathy in type 2 diabetes mellitus. Int J Diabetes Res. 2018;7(3):41–9. https://doi.org/10.5923/j.diabetes.20180703.01.

Article  Google Scholar 

Mezil SA, Ghudhaib KK, Allawi AA. Evaluation of serum pentraxin 3 level in Iraqi patients with diabetic nephropathy. Biochem Cell Arch. 2018;18:2473–7.

Google Scholar 

Valente MJ, Rocha S, Coimbra S, Catarino C, Rocha PP, Bronze-da-Rocha E, et al. Long pentraxin 3 as a broader biomarker for multiple risk factors in end-stage renal disease: association with all-cause mortality. Mediators of Inflammation. 2019;2019:1–12.

Article  Google Scholar 

Zlibut A, Bocșan IC, Agoşton-Coldea L. Pentraxin-3 and endothelial dysfunction. Adv Clin Chem. 2019;1:163–79.

Article  Google Scholar 

Lestariningsih L, Hardisaputro S, Nurani A, Santosa D, Santoso G. High sensitivity C-reactive protein as a predictive of intima-media thickness in patients with end-stage renal disease on regular hemodialysis. Int J Gen Med. 2019;12:219–24. https://doi.org/10.2147/ijgm.s205506. (Internet).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sjöberg B, Qureshi AR, Heimbürger O, Stenvinkel P, Lind L, Larsson A, et al. Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly. J Intern Med. 2016;279(2):173–9. https://doi.org/10.1111/joim.12411. (Internet).

Article  CAS  PubMed  Google Scholar